NicOx SA has confirmed its plans to submit regulatory applications in the US and Europe by the end of 2009 for its anti-inflammatory agent, naproxcinod, which has been developed to relieve the signs and symptoms of osteoarthritis. ---Subscribe to MedNous to access this article--- Company News
